Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ALGORITM

Financiado

Cerrado

Applying human lung tissue models to develop a personalised treatment for critic...

Applying human lung tissue models to develop a personalised treatment for critically ill Acute respiratory distress syndrome (ARDS) is a major cause of mortality in the critically ill patients with no effective pharmacological treatment. Recently, two distinct endotypes of ARDS were identified and validated in four la... ver más

31/03/2023

THE QUEEN'S UNIVER...

213K€

Presupuesto del proyecto: 213K€

Líder del proyecto

THE QUEENS UNIVERSITY OF BELFAST No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-03-31

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE QUEEN'S UNIVERSITY OF BE...

212.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CCMI-ARDS Medically Licensed Mesenchymal Stem Cells for Acute Respirat... 149K€ Cerrado

PID2020-113910RB-I00 CONDICIONAMIENTO BIOFISICO DE CELULAS MADRE/ESTROMALES MESEN... 218K€ Cerrado

SECRET Exploring the therapeutic potential of perinatal cell SECRET... Cerrado

TWINFLAG Twinning for Promoting Excellence, Ability and Knowledge to... 2M€ Cerrado

ADIPOA2 Clinical trial of autologous adipose derived mesenchymal str... 6M€ Cerrado

TREG TREG innovative cell therapy targeting Diabetes Type 1 4M€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2020-11-18
Fecha Fin: 2023-03-31

Líder del proyecto

THE QUEENS UNIVERSITY OF BELFAST No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 213K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Acute respiratory distress syndrome (ARDS) is a major cause of mortality in the critically ill patients with no effective pharmacological treatment. Recently, two distinct endotypes of ARDS were identified and validated in four large randomized controlled trials: a hyper-inflammatory and a hypo-inflammatory endotype. These endotypes have strikingly different clinical characteristics, biomarker profiles, clinical outcomes, and treatment responses. While these data are highly promising, the biology of these endotypes is not understood. Mesenchymal Stem Cells (MSCs) hold significant therapeutic promise for ARDS and are rapidly progressing to clinical trials across the world. However, concern for the use of stem cells, specifically the risk of tumor formation, remains unresolved. Accumulating evidence suggests that MSCs exert their therapeutic benefit through the release of extracellular vesicles (EVs). MSC EVs are being actively developed as a cell free therapy for ARDS, but for the effective clinical translation it is important to establish EV therapeutic potential for both biological endotypes of patients. In this project, I am going to use cutting edge technology and employ the most physiological human lung tissue models to date to study the biology of ARDS endotypes and to test therapeutic potential of MSC EVs. The main objectives are: i) To reveal how endotype–specific environments alter human lung tissue and how these changes are affected by EV treatment at a single cell level, using single cell RNA-Seq transcriptomic profiling of precision-cut human lung tissue slices, ii) to study how endotype-specific environments (with or without EV treatment) alter functional properties of the alveolar epithelial-endothelial barrier using lung-on-a-chip microfluidic model, iii) to study how endotype-specific environments (with or without EVs) alter metabolism of the primary human pulmonary cells involved in ARDS pathophysiology using Seahorse Metabolic Analyser.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores